## Hans M Westgeest

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5141067/publications.pdf

Version: 2024-02-01

933447 794594 26 392 10 19 citations g-index h-index papers 26 26 26 841 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. Clinical Cancer Research, 2022, 28, 215-226.	7.0	5
2	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. Clinical Genitourinary Cancer, 2022, 20, 43-52.	1.9	3
3	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. Drugs - Real World Outcomes, 2022, , 1.	1.6	O
4	Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, e346-e352.	1,9	5
5	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Oncology, 2021, 4, 618-627.	5 <b>.</b> 4	6
6	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 2021, 7, 788-796.	3.1	1
7	Impact of <scp>DNA</scp> damage repair defects and aggressive variant features on response to carboplatinâ€based chemotherapy in metastatic castrationâ€resistant prostate cancer. International Journal of Cancer, 2021, 148, 385-395.	5.1	28
8	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. Prostate Cancer and Prostatic Diseases, 2021, 24, 871-879.	3.9	8
9	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. Journal of Palliative Medicine, 2021, 24, 1789-1797.	1.1	4
10	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 2021, 13, 4639.	3.7	9
11	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. European Urology Oncology, 2020, 3, 231-238.	5 <b>.</b> 4	30
12	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. Clinical Genitourinary Cancer, 2020, 18, e233-e253.	1.9	4
13	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 2020, 16, 1371-1384.	2.4	25
14	A clinician's guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2067-2075.	2.5	5
15	Case report. Zeldzame cutane metastasering van urotheelcelcarcinoom twee jaar na cystectomie. Tijdschrift Voor Urologie, 2020, 10, 2-4.	0.1	O
16	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	1.6	83
17	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical Genitourinary Cancer, 2019, 17, e946-e956.	1.9	5
18	An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. Journal of Molecular Diagnostics, 2018, 20, 316-325.	2.8	15

#	Article	IF	CITATION
19	Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 2018, 4, 694-701.	3.1	43
20	Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. Value in Health, 2017, 20, 627-636.	0.3	27
21	CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrateâ€resistant prostate cancer previously treated with docetaxel. International Journal of Cancer, 2015, 136, E760-72.	5.1	34
22	Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure. Journal of Clinical Oncology, 2013, 31, e83-e86.	1.6	13
23	Recurrent Dyspnea Following a Swollen Leg in a 46-Year-Old Man. Chest, 2013, 144, 1402-1405.	0.8	0
24	European School of Internal Medicine (ESIM) in Brighton. European Journal of Internal Medicine, 2011, 22, 238-240.	2.2	0
25	Bone pain and extremely low bone mineral density due to severe vitamin D deficiency in celiac disease. Archives of Osteoporosis, 2011, 6, 209-213.	2.4	28
26	Pure naratriptan-induced ischemic colitis: A case report. Turkish Journal of Gastroenterology, 2010, 21, 42-44.	1.1	11